All In Biotech

Drug Trial Radar · NCT07335497

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Feb 17, 2026

Primary completion

Feb 2029

Study completion Feb 2029

Sponsor

Lead sponsor
Crescent Biopharma, Inc.Industry
Sponsor type
Industry
First posted
Jan 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.

Conditions

  • Locally Advanced / Metastatic Solid Tumors

Interventions

  • CR-001Drug

    Intravenous Infusion

  • PaclitaxelDrug

    Intravenous Infusion

  • trifluridine and tipiracilDrug

    Oral

  • PemetrexedDrug

    Intravenous Infusion

  • CarboplatinDrug

    Intravenous Infusion

  • OxaliplatinDrug

    Intravenous Infusion

  • GemcitabinDrug

    Intravenous Infusion

  • CisplatinDrug

    Intravenous Infusion

  • CapecitabineDrug

    Oral

  • FOLFOXDrug

    Intravenous Infusion + Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 (Dose Escalation) - Incidence and nature of dose-limiting toxicitiesTime frame: From the first dose of study drug up until approximately 1 month
  2. Part 1 (Dose Escalation) - Characterization of the maximum tolerated dose, if applicableTime frame: From the first dose of study drug up until approximately 1 month
  3. All parts - Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and treatment - emergent serious adverse eventsTime frame: From the first dose of study drug until 90 days after the last dose of study drug
  4. All parts - Incidence and severity of TEAEs leading to dose modificationsTime frame: From the first dose of study drug until 90 days after the last dose of study drug
  5. All parts - Incidence and severity of TEAEs leading to treatment discontinuationTime frame: From the first dose of study drug until 90 days after the last dose of study drug
  6. Part 3 (Dose Expansion) - Overall response rate (ORR) by Investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)Time frame: From the first dose of study drug until 90 days after the last dose of study drug

Locations

36 sites in 10 countries. Site status is shown where the registry gives one.

  • Clinical Study Site

    Birmingham, Alabama · Recruiting

  • Clinical Study Site

    Los Angeles, California · Recruiting

  • Clinical Study Site

    Denver, Colorado · Recruiting

  • Clinical Study Site

    Washington D.C., District of Columbia · Recruiting

  • Clinical Study Site

    Orlando, Florida · Recruiting

  • Clinical Study Site

    Sarasota, Florida · Recruiting

  • Clinical Study Site

    Detroit, Michigan · Recruiting

  • Clinical Study Site

    Grand Rapids, Michigan · Recruiting

  • Clinical Study Site

    New York, New York · Recruiting

  • Clinical Study Site

    Columbus, Ohio · Recruiting

  • Clinical Study Site

    Pittsburgh, Pennsylvania · Recruiting

  • Clinical Study Site

    Nashville, Tennessee · Recruiting

  • Clinical Study Site

    Dallas, Texas · Recruiting

  • Clinical Study Site

    San Antonio, Texas · Recruiting

  • Clinical Study Site

    West Valley City, Utah · Recruiting

  • Clinical Study Site

    South Brisbane, Queensland, Australia · Withdrawn

  • Clinical Study Site

    Villejuif, France · Recruiting

  • Clinical Study Site

    Dublin, Ireland, Ireland · Recruiting

  • Clinical Study Site

    Florence, Italy · Recruiting

  • Clinical Study Site

    Milan, Milano, Italy · Recruiting

  • Clinical Study Site

    Candiolo, Torino, Italy · Recruiting

  • Clinical Study Site

    Bucharest, Romania · Recruiting

  • Clinical Study Site

    Cluj-Napoca, Cluj, Romania · Recruiting

  • Clinical Study Site

    Seongnam-si, South Korea · Recruiting

  • Clinical Study Site

    Seoul, Seoul, South Korea · Recruiting

  • Clinical Study Site

    Seoul, Seoul, South Korea · Recruiting

  • Clinical Study Site

    Seoul, Seoul, South Korea · Recruiting

  • Clinical Study Site

    Songpa-dong, Seoul, South Korea · Recruiting

  • Clinical Study Site

    Barcelona, Barcelona, Spain · Recruiting

  • Clinical Study Site

    Logroño, La Rioja, Spain · Recruiting

  • Clinical Study Site

    Madrid, Madrid, Spain · Recruiting

  • Clinical Study Site

    Madrid, Madrid, Spain · Recruiting

  • Clinical Study Site

    Kyiv, Ukraine · Recruiting

  • Clinical Study Site

    Hampstead, United Kingdom · Recruiting

  • Clinical Study Site

    London, United Kingdom · Recruiting

  • Clinical Study Site

    Manchester, Greater Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.